Sign In
Buy CERT
$8.10
+0.320 (+4.11%)
At Close: Jul 31, 2026
CERT Investors Have Opportunity to Join Certara, Inc. Fraud Investigation with the Schall Law Firm
02:14pm, Sunday, 24'th May 2026
LOS ANGELES, May 24, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Certara, Inc. (“
CERT SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
07:00pm, Friday, 22'nd May 2026
NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Certara, Inc. (“Certara” or the “Company”) (NASDAQ:CERT) inv
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT
06:40pm, Thursday, 21'st May 2026
NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. ("Certara" or the "Company") (NASDAQ: CERT). Such investors are advised to contact
CERT SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
06:00pm, Wednesday, 20'th May 2026
NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Certara, Inc. (“Certara” or the “Company”) (NASDAQ:CERT) investors concerning
Certara, Inc. (CERT) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
05:40pm, Tuesday, 19'th May 2026
Certara, Inc. (CERT) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
CERT SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
07:00pm, Monday, 18'th May 2026
NEW YORK, May 18, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Certara, Inc. (“Certara” or the “Company”) (NASDAQ:CERT) inv
Certara to Participate in Upcoming Investor Conferences
04:15pm, Monday, 18'th May 2026
RADNOR, Pa., May 18, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the followin
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Certara (CERT) To Contact Him Directly To Discuss Their Options
CERTARA, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
06:00pm, Wednesday, 13'th May 2026
NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Certara, Inc. (“Certara” or the “Company”) (NASDAQ:CERT). The investigation concerns wh
SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Certara, Inc. (NASDAQ: CERT). The investigation focuses on Certara's execut
Certara, Inc. (CERT) Q1 2026 Earnings Call Transcript
01:00pm, Monday, 11'th May 2026
Certara, Inc. (CERT) Q1 2026 Earnings Call Transcript
Certara Q1 Earnings Call Highlights
10:07am, Monday, 11'th May 2026
Certara NASDAQ: CERT reported first-quarter 2026 revenue of $106.9 million, up 1% from the prior-year period, as stronger software performance offset softer services results and the company outlined a
Certara, Inc. (CERT) Q1 Earnings Miss Estimates
08:46am, Monday, 11'th May 2026
Certara, Inc. (CERT) came out with quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.14 per share a year ago.
Certara Reports First Quarter 2026 Financial Results
06:25am, Monday, 11'th May 2026
Updates 2026 Guidance to reflect completed divestiture of Regulatory Writing and Medical Writing Business Updates 2026 Guidance to reflect completed divestiture of Regulatory Writing and Medical Writi
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development
08:00am, Thursday, 07'th May 2026
LAVAL, Québec & RADNOR, Pa.--(BUSINESS WIRE)-- #Altasciences--Altasciences, a fully integrated drug development solution company, and Certara (Nasdaq: CERT), a global leader in model-informed drug de
